Subgroup analysis of CP-B patients demonstrated a gradational decline: CP-B7 patients maintained an mPFS of 11 months (95% CI 6.6-15.4), whereas those with CP-B8–9 showed faster progression with an mPFS of 7 months (95% CI 5.3-8.7; Figure 3b). This evidence concerns the gene CP and carotid plaque build.